FDA Grants Priority Review for Zoliflodacin with Dec 2025 PDUFA
FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin...
Tag : New Drug Application
Innoviva Files for Zoliflodacin, a New Oral Antibiotic for Gonorrhea
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that...
InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its new generation pan-TRK inhibitor zurletrectinib...